HLB Co., Ltd. 028300

In March, the FDA granted Priority Review of Lyrfigtu (lirafugratinib); PDUFA date of September 25, 2026 Lyrfigtu (lirafugratinib) achieved a 46% ORR, in CCA patients with FGFR2 fusion or other rearrangement Fort Lee, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced the U.S. Food and Drug Ad

Submission initiates regulatory process in European Union following U.S. submission, expanding global market presenceLirafugratinib is a highly selective, irreversible FGFR2 inhibitor differentiated from existing pan-FGFR therapies FORT LEE, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced t

In post hoc analysis of CARES-310 trial, combination improved mPFS versus sorafenib across age subgroupsCombination also improved mOS versus sorafenib in patients <50 years and ≥50 yearsElevar is sponsoring Sept. 3 welcome reception at ILCA Annual Conference BRUSSELS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patien